Spyre Therapeutics Stock Forum

RECAP
U.S. stocks advanced on Monday, building off a record finish ahead of the ramping up of fourth-quarter earnings season.
The $Dow Jones Industrial Average(.DJI.US)$ rose 138 points, or 0.26%, to 38,000. The $S&P 500 Index(.SPX.US)$ was up 10 points, or 0.22%, at 4,850. The $Nasdaq Composite Index(.IXIC.US)$advanced 49 points, or 0.32%, to 15,360.
While the S&P 500 finally returned to record territory on Friday, skeptic...

After two major indexes reached all-time highs, pharmaceutical stocks for companies in drug trials were caught up in the energy and rocketed forward. The largest gainers were $Spyre Therapeutics(SYRE.US)$, up 26% Monday morning, and $Gyre Therapeutics(GYRE.US)$ +10%.
Spyre felt the positive pressure from fresh buy ratings by analysts like Stifel. $Ginkgo Bioworks(DNA.US)$ also roase 9%, despite a new sell rating from Goldman Sachs.
But monday morning was not al...